TORONTO, March 26 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today reported operational and financial results for the fourth quarter and year ended December 31, 2007.
"This was a transformative year for GeneNews because of the
advancements made for the laboratory-developed test (LDT) version of
ColonSentry(TM) and the strengthening of our internal processes and
systems," said Dr. K. Wayne Marshall, MD, PhD, President and CEO of
GeneNews. "We are now positioned for the initial commercial launch of
ColonSentry in the third quarter of 2008 through our in-house clinical
reference lab located in the Toronto-area."
- Completed collection of 10,000 patient samples for internal
validation studies of ColonSentry.
- Initiated the collection of patient samples for additional clinical
trials for the development of an In Vitro Diagnostic (IVD) version of
ColonSentry in December.
- Subsequent to year-end in January 2008, published a paper entitled
"Novel Blood-Based, Five-Gene Biomarker Set for the Detection of
Colorectal Cancer" in the Clinical Cancer Research journal.
- Subsequent to year-end on March 14, 2008, received notification that
an abstract entitled "Stratification of colorectal cancer probability
using six genes from whole blood" was selected for presentation on
April 15, 2008 at the annual meeting of the American Association of
Cancer Research to be held in San Diego, California.
- Implemented a Quality Management System to conform to ISO 13485:2003
requirements and, subsequent to year end, received formal
certification on March 6, 2008 for the design and development of
in-vitro diagnostic test
|SOURCE GeneNews Limited|
Copyright©2008 PR Newswire.
All rights reserved